Drugs / Product 0405
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01232543 | Nov 2010 → Aug 2011 | atopic eczema | Fougera Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02176551 | Jun 2012 → May 2013 | atopic eczema | Fougera Pharmaceuticals Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02176538 | Jun 2012 → May 2013 | atopic eczema | Fougera Pharmaceuticals Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02176577 | Jun 2012 → May 2013 | atopic eczema | Fougera Pharmaceuticals Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Product 0405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02176551 ↗ |
| Route | Topical | “Product 0405 will be administered topically, twice daily for 28 days.” NCT01232543 ↗ |